Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat Media Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters MostWritten by Chris Markoch. Posted: 2/5/2026. 
Key Points - Pfizer stock jumped after a beating on the top and bottom lines, but the rally may reflect more than just strong quarterly results and short-term GLP-1 excitement.
- Positive Phase 2b GLP-1 obesity data gives Pfizer optionality, though meaningful revenue from weight-loss drugs is still several years away.
- An expanding oncology pipeline and AI-driven R&D strategy could be the most overlooked long-term growth catalysts for PFE.
Pfizer Inc. (NYSE: PFE) helped lift the Dow Jones Industrial Average after delivering a double beat in its fourth-quarter earnings report. Revenue of $17.56 billion topped analysts' estimates of $16.93 billion. On the bottom line, Pfizer delivered adjusted earnings per share (EPS) of $0.69, beating estimates of $0.57. A highlight of the report was Pfizer's announcement of positive topline results from the Phase 2b study for its lead GLP-1 drug candidate. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> PFE stock closed up 4% on Feb. 4 as analysts and investors digested the report. The bullish thesis is that while GLP-1 headlines may drive near-term excitement, Pfizer's more durable upside is likely to come from its expanding oncology pipeline and its accelerating use of artificial intelligence across R&D. That starts with the company's push into obesity, where it reported a notable clinical update alongside the quarter. Pfizer Wants a Piece of the Weight-Loss Drug Pie The weight-loss drug market is expanding rapidly. Data show the global GLP-1 market will grow from $62.2 billion in 2025 to $157 billion by 2035. That implies a compound annual growth rate (CAGR) of about 9.7%, which helps explain why billions of dollars are flowing into the industry as companies try to carve out market share. For Pfizer, the opportunity centers on its lead GLP-1 candidate, MET-097i. The company announced results from its Phase 2b VESPER-3 study: the trial met its primary endpoint and showed a statistically significant, placebo-adjusted weight loss of up to 12.3% at 28 weeks. Pfizer also noted that patients continued to lose weight after transitioning from weekly to monthly dosing, with no plateau observed by the end of the 28 weeks. The Growth Driver Investors May Be Missing Immediately after the report, attention naturally focused on the positive clinical trial results as the reason for the stock's gain. That may be true, but investors should be cautious—GLP-1 enthusiasm can drive a near-term sugar high. While Pfizer's GLP-1 program looks promising, it will take time for meaningful revenue to flow to the company's bottom line. The GLP-1 trade is also expanding, and the largest players in Big Pharma are aggressively defending market share. As Eli Lilly & Co. (NYSE: LLY) demonstrated in its recent earnings report, incumbents aren't stepping aside. There are other reasons to be bullish on PFE, notably its oncology portfolio. Business Research Insights values the global oncology drugs market at roughly $264.92 billion in 2026 and projects it to climb to $648.08 billion by 2035, reflecting a CAGR of about 10.3%. A Growing Pipeline Gives Pfizer Many Shots on Goal As of late 2025, Pfizer had approximately 60 candidates in its pipeline, offering numerous opportunities to capture market share. The company's portfolio was significantly strengthened by its acquisition of Seagen in 2023. Today, Pfizer's pipeline includes late-stage candidates such as vepdegestrant, a next-generation targeted protein degrader (PROTAC), paired with atirmociclib, a selective CDK4 inhibitor, for ER+/HER2- metastatic breast cancer in later-stage trials. Pfizer also has other late-stage programs, including: - Sigvotatug vedotin, an antibody-drug conjugate (ADC) in Phase 3 testing (e.g., Be6A LUNG-01) for metastatic non-small cell lung cancer, leveraging Seagen-acquired ADC expertise.
- Sasanlimab, which targets bladder cancer, and a bispecific PD-1xVEGF agent (PF-4404) that combines with Padcev to treat urothelial cancer—positions that could yield blockbusters amid oncology growth.
Pfizer could bring multiple drugs to market over the next five to 10 years. That outlook is reinforced by the company's growing commitment to artificial intelligence (AI), which is becoming essential to many stocks in the biopharmaceutical sector. Pfizer integrates AI across R&D through partnerships with firms like Boltz (biomolecular modeling), XtalPi (molecular design), and Data4Cure (oncology data analytics), accelerating target identification—Pfizer says tools like OncoScout can speed that process by at least 50%. Internally, platforms such as "Charlie" handle data mining, predictions, and content generation, while collaborations with NVIDIA (NASDAQ: NVDA) optimize discovery and manufacturing. These efforts were important in the company's rapid development of Paxlovid and support 2026 catalysts in oncology and obesity. Pfizer is targeting $1.2 billion in savings by 2027 through efficiency gains. Industry-wide, AI is projected to boost productivity 35% to 45% by improving preclinical decisions and trial design, making it a core competitive advantage rather than optional hype. Pfizer has positioned itself near the forefront of AI adoption in drug discovery, which should benefit investors over the medium and long term.
| 
